Know Cancer

or
forgot password

Data, Tissue, Blood, and Urine Repository for Amyloid Diseases


N/A
18 Years
N/A
Open (Enrolling)
Both
Multiple Myeloma and Plasma Cell Neoplasm

Thank you

Trial Information

Data, Tissue, Blood, and Urine Repository for Amyloid Diseases


OBJECTIVES:

- To establish and maintain a database of clinical material (i.e., blood, urine, and
tissue) and information on patients with primary systemic amyloidosis.

OUTLINE: Blood, urine, tissue, and bone marrow samples are collected during standard
laboratory evaluations to maintain a repository of biospecimens in the Gerry Amyloid
Research Laboratory, to permit the correlation of clinical results with measured biological
events, and for future research studies. Bone marrow RNA samples are examined for
immunoglobulin light-chain gene sequences and amino acids by PCR and positional cloning.
Blood serum and urine samples are evaluated for amyloid protein stability by high-resolution
calorimetry, isothermal-titration calorimetry, and far- and near-UV circular dichroism and
fluorescence spectroscopy. Urine samples are also examined for post-translational
modifications (e.g., glycosylation, sulfation, and cross-linking) to identify common
features unique to amyloid proteins. Tissue samples are analyzed for biochemical and
biophysical properties and for post-translational modifications in light chains.

Quality of life is assessed by the SF36 questionnaire.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Diagnosis or suspicion of primary systemic amyloidosis

PATIENT CHARACTERISTICS:

- Referred to the Amyloid Treatment and Research Center at Boston University Medical
Center

PRIOR CONCURRENT THERAPY:

- Not specified

Type of Study:

Observational

Study Design:

Time Perspective: Prospective

Outcome Measure:

Collection of clinical material and information

Outcome Time Frame:

life of study

Safety Issue:

No

Principal Investigator

David C. Seldin, MD, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Boston Medical Center

Authority:

United States: Food and Drug Administration

Study ID:

CDR0000632869

NCT ID:

NCT00898235

Start Date:

January 2000

Completion Date:

February 2037

Related Keywords:

  • Multiple Myeloma and Plasma Cell Neoplasm
  • primary systemic amyloidosis
  • Amyloidosis
  • Neoplasms
  • Multiple Myeloma
  • Neoplasms, Plasma Cell
  • Plasmacytoma

Name

Location

Boston University Cancer Research CenterBoston, Massachusetts  02118